Robert Lai

58 papers receiving 2.6k citations

Hit Papers

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody 2021 · 580 citations
5802021202620222024100200300400500

Peers

Robert Lai
Comparison fields: 5 of 126
  • Physiology 1.6k
  • Biological Psychiatry 111
  • Sensory Systems 200
  • Neurology 308
  • Pharmacology 614
Replace Katsuya Urakami with:
Katsuya Urakami Japan
Nobuya Matsuoka Japan
Thomas G. Ohm Germany
Anete Rozkalne United States
Mark R. Emmerling United States
Hitoshi Shinotoh Japan
Paulina V. Arriagada United States
Ernesto Fedele Italy
Tracey K. Murray United Kingdom
R. G. Struble United States
Robert Lai relative to Katsuya Urakami Japan Katsuya Urakami's profile →
Citations per field
00.5×1.5×2.5×
Katsuya Urakami · 1×
Citations per year

Countries citing papers authored by Robert Lai

Since Specialization
Citations

This map shows the geographic impact of Robert Lai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Lai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Lai more than expected).

Fields of papers citing papers by Robert Lai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Lai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Lai. The network helps show where Robert Lai may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert Lai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert Lai Line = papers co-authored together Robert Lai links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 61 papers — load more, or switch the sort, to bring in the rest.

#Work
1
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Hit paper breakdown →
2021580
2 1996438
3 2016212
4 2007199
5 2011133
6 2004103
7 201298
8 201088
9 200183
10 201055
11 201354
12 199551
13 199550
14 201246
15 201341
16 201140
17 200836
18 201434
19 201033
20 201229

About Robert Lai

Robert Lai is a scholar working on Physiology, Sensory Systems, Psychiatry and Mental health, Pharmacology and Cognitive Neuroscience, having authored 61 papers that have together received 2.7k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (23 papers), Cholinesterase and Neurodegenerative Diseases (11 papers), Computational Drug Discovery Methods (8 papers), Dementia and Cognitive Impairment Research (7 papers), Neural and Behavioral Psychology Studies (6 papers), Phosphodiesterase function and regulation (5 papers), 14-3-3 protein interactions (5 papers) and Neural dynamics and brain function (5 papers). The work is most often cited by research in Physiology (1.6k citations), Biological Psychiatry (111 citations), Sensory Systems (200 citations), Neurology (308 citations) and Pharmacology (614 citations). Robert Lai has collaborated with scholars based in United Kingdom, United States and Japan. Frequent co-authors include Claude M. Wischik, Charles R. Harrington, Patricia C. Edwards, Martin Roth, June Kaplow, Chad J. Swanson, Lars Lannfelt, Boris A. Chizh, Neil Upton and Jinping Wang. Their work appears in journals such as Alzheimer s & Dementia, Neurobiology of Aging, European Journal of Pain, Alzheimer s Research & Therapy and Journal of Nuclear Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026